Zhang Y
Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
Clin Pharmacol Ther. 2007 Nov;82(5):595-600. doi: 10.1038/sj.clpt.6100362. Epub 2007 Sep 26.
The current 6-month tuberculosis (TB) therapy is suboptimal with significant side effects and a poor patient compliance problem that frequently selects drug-resistant organisms. The increasing drug-resistant TB problem highlights the need to develop new and more effective drugs. Significant progress has been made recently with several new drug candidates currently in clinical trials. Improved understanding of persister biology and development of persister drugs are likely to be important for developing a more effective therapy.
目前为期6个月的结核病治疗并不理想，存在显著的副作用以及患者依从性差的问题，这常常导致耐药菌的产生。结核病耐药问题日益严重，凸显了研发新型更有效药物的必要性。最近，几种新药候选物已进入临床试验阶段，并取得了重大进展。更好地理解持留菌生物学特性以及开发针对持留菌的药物，对于研发更有效的治疗方法可能至关重要。
